Conway Regional Medical Center INC

Conway Regional Medical Center INC was paid $10.63M by Medicaid between Jan 2018 and Dec 2024, across 321 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 6.9% of everything it billed.

Compared with peers

Next to other General Acute Care Hospital providers in Arkansas

Rank by total paid#9 of 49

Median peer was paid$2.62M

This provider vs. median4.1×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	77,059	$1.08M
2019	80,256	$1.20M
2020	71,797	$1.25M
2021	82,149	$1.74M
2022	86,412	$1.92M
2023	100,946	$2.00M
2024incomplete	76,366	$1.44M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	6.9%	8,340	7,490	$729K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	6.2%	16,537	4,565	$659K
80053	Comprehensive metabolic panel	4.6%	39,149	31,274	$486K
74177	Computed tomography, abdomen and pelvis; with contrast material	4.4%	3,550	3,275	$464K
70450	Computed tomography, head or brain; without contrast material	3.6%	3,905	3,576	$378K
80050	General health panel	3.5%	7,782	7,382	$367K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.1%	5,018	4,388	$328K
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	2.4%	1,052	1,041	$258K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	2.3%	3,478	2,603	$245K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	2.0%	3,410	2,894	$207K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.9%	6,338	4,897	$204K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.9%	8,279	6,436	$202K

309 more codes

85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.9%	33,789	$200K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.9%	11,260	$198K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	1.7%	690	$185K
86008		1.7%	789	$182K
80061	Lipid panel	1.5%	14,992	$163K
88305	Level IV - Surgical pathology, gross and microscopic examination	1.5%	2,947	$158K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	1.5%	1,006	$154K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	1.4%	5,032	$151K
84443	Thyroid stimulating hormone (TSH)	1.4%	15,853	$149K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.4%	1,316	$144K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.3%	3,385	$135K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	1.3%	1,032	$134K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.3%	3,380	$134K
72125	Computed tomography, cervical spine; without contrast material	1.0%	948	$107K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	10,902	$106K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	336	$102K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	580	$94K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	3,546	$92K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	2,487	$91K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	1,338	$90K
71046	Radiologic examination, chest; 2 views	<1%	5,198	$90K
80048	Basic metabolic panel (calcium, ionized)	<1%	8,721	$89K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	662	$83K
87086	Culture, bacterial; quantitative colony count, urine	<1%	10,670	$81K
59025	Fetal non-stress test	<1%	396	$77K
81025		<1%	8,710	$74K
86901		<1%	3,245	$71K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	183	$66K
97162		<1%	578	$64K
83036	Hemoglobin; glycosylated (A1C)	<1%	7,880	$63K
85027		<1%	11,126	$63K
87070		<1%	7,201	$62K
97161		<1%	1,019	$55K
83690		<1%	7,818	$54K
81001		<1%	16,151	$52K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	2,732	$51K
82150		<1%	7,759	$50K
84439		<1%	6,168	$49K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	1,252	$49K
71045	Radiologic examination, chest; single view	<1%	5,830	$48K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,118	$42K
82607		<1%	3,299	$39K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	2,419	$38K
82553		<1%	4,284	$38K
86141		<1%	3,404	$36K
84484		<1%	4,925	$36K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	164	$36K
85730		<1%	6,597	$35K
72110		<1%	1,085	$35K
96361	Intravenous infusion, hydration; each additional hour	<1%	712	$35K
82728		<1%	3,218	$34K
96375	Therapeutic injection; each additional sequential IV push	<1%	2,501	$32K
83880		<1%	1,444	$31K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,004	$31K
87186		<1%	4,938	$29K
82565		<1%	2,537	$28K
80320		<1%	1,614	$28K
74018		<1%	1,403	$28K
85610		<1%	7,701	$27K
84145		<1%	1,448	$27K
82948		<1%	4,067	$27K
99283	Emergency room visit (moderate)	<1%	2,027	$26K
82550		<1%	5,089	$26K
99284	Emergency room visit (serious)	<1%	5,171	$26K
73630		<1%	1,012	$26K
87040		<1%	1,722	$25K
97001		<1%	569	$24K
87077		<1%	2,773	$23K
87806		<1%	932	$22K
76642		<1%	801	$21K
70486		<1%	165	$21K
83540		<1%	3,932	$21K
82746		<1%	1,970	$20K
83735		<1%	4,508	$20K
86003		<1%	334	$19K
80347		<1%	959	$19K
49452		<1%	226	$19K
77066	Tomosynthesis, mammo	<1%	275	$18K
84702		<1%	1,817	$18K
80329		<1%	1,079	$18K
77063	Screening digital breast tomosynthesis, bilateral	<1%	1,987	$18K
86803		<1%	1,299	$18K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	11,036	$17K
83605		<1%	1,815	$17K
86850		<1%	2,671	$17K
97165		<1%	305	$17K
83550		<1%	2,325	$16K
73610		<1%	861	$16K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	609	$16K
73564		<1%	481	$15K
73030		<1%	735	$15K
84153		<1%	975	$14K
82785		<1%	825	$14K
80074		<1%	295	$14K
80047		<1%	509	$13K
82570		<1%	2,914	$13K
80326		<1%	671	$12K
80349		<1%	631	$12K
84403		<1%	424	$11K
86225		<1%	1,008	$11K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	88	$11K
87088		<1%	1,420	$11K
87340		<1%	1,117	$11K
82947		<1%	1,401	$10K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	559	$10K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	3,367	$10K
87015		<1%	1,497	$10K
88312		<1%	1,067	$10K
72050		<1%	427	$10K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	492	$10K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	5,654	$10K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	111	$10K
85007		<1%	2,835	$9K
86706		<1%	923	$9K
86900		<1%	3,247	$9K
83516		<1%	414	$9K
86039		<1%	970	$9K
87205		<1%	2,394	$9K
84132		<1%	1,094	$9K
42820	Tonsillectomy and adenoidectomy; younger than age 12	<1%	25	$9K
72141		<1%	40	$9K
87899		<1%	1,287	$9K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	179	$9K
87507		<1%	12	$8K
81003		<1%	4,127	$8K
82435		<1%	877	$8K
88304		<1%	345	$8K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	297	$8K
85379		<1%	833	$8K
86780		<1%	443	$8K
82247		<1%	1,466	$7K
95957		<1%	340	$7K
C1769	Guide wire	<1%	763	$7K
74019		<1%	353	$7K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	4,967	$7K
82043		<1%	1,410	$7K
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	398	$7K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	33	$7K
71275	Computed tomographic angiography, chest, with contrast material	<1%	42	$7K
84480		<1%	571	$7K
80364		<1%	595	$7K
95819		<1%	143	$6K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	455	$6K
84295		<1%	959	$6K
99285	Emergency room visit (most serious)	<1%	854	$6K
J2785	Injection, regadenoson, 0.1 mg	<1%	28	$6K
86708		<1%	505	$6K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	154	$6K
80051		<1%	1,279	$6K
80076		<1%	767	$6K
73110		<1%	250	$5K
84520		<1%	1,240	$5K
71020		<1%	407	$5K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	25	$5K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,869	$5K
85652		<1%	1,931	$5K
62323		<1%	26	$5K
86704		<1%	472	$5K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	365	$5K
82248		<1%	1,012	$5K
Q3014	Telehealth originating site facility fee	<1%	742	$5K
87420		<1%	408	$5K
87430		<1%	363	$5K
84100		<1%	1,971	$4K
73130		<1%	201	$4K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	29	$4K
72070		<1%	204	$4K
76830	Ultrasound, transvaginal	<1%	108	$4K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	123	$4K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	115	$4K
85014		<1%	1,630	$4K
86592		<1%	922	$4K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	47	$4K
84156		<1%	859	$4K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	95	$4K
83525		<1%	460	$4K
84146		<1%	134	$4K
93971		<1%	100	$3K
87045		<1%	357	$3K
0002A		<1%	215	$3K
83970		<1%	127	$3K
85651		<1%	1,556	$3K
76775		<1%	167	$3K
86480		<1%	44	$3K
J2704	Injection, propofol, 10 mg	<1%	5,957	$3K
84238		<1%	278	$3K
86431		<1%	561	$3K
82105		<1%	165	$3K
82805		<1%	116	$3K
84550		<1%	841	$3K
64635		<1%	15	$2K
82330		<1%	117	$2K
49450		<1%	25	$2K
36430		<1%	14	$2K
64493		<1%	33	$2K
76536		<1%	55	$2K
85018		<1%	824	$2K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	968	$2K
87210		<1%	391	$2K
0001A		<1%	189	$2K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	381	$2K
J0690	Injection, cefazolin sodium, 500 mg	<1%	2,692	$2K
83615		<1%	607	$2K
73502		<1%	58	$2K
74000		<1%	107	$2K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	4,562	$2K
87634		<1%	23	$2K
77065	Tomosynthesis, mammo	<1%	30	$2K
82784		<1%	214	$1K
86376		<1%	90	$1K
77080		<1%	59	$1K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	12	$1K
71010		<1%	159	$1K
82670		<1%	45	$1K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	309	$1K
87653		<1%	25	$1K
84481		<1%	176	$1K
96376		<1%	215	$1K
86757		<1%	37	$1K
84144		<1%	42	$1K
87046		<1%	559	$1K
80165		<1%	101	$1K
87493		<1%	83	$987.05
90714		<1%	114	$972.81
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	553	$931.08
77062		<1%	12	$901.17
86256		<1%	56	$775.17
83655		<1%	44	$725.76
80164		<1%	81	$709.41
86920		<1%	16	$680.00
84450		<1%	206	$677.52
73080		<1%	26	$654.71
72170		<1%	44	$642.14
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	103	$616.85
99152		<1%	293	$601.13
88307		<1%	26	$583.00
86666		<1%	45	$581.20
83001		<1%	24	$566.53
75984		<1%	385	$560.02
J2270	Injection, morphine sulfate, up to 10 mg	<1%	3,386	$524.86
72100		<1%	28	$518.70
84436		<1%	177	$495.25
86200		<1%	34	$472.30
72120		<1%	17	$465.81
73120		<1%	35	$464.15
86618		<1%	33	$442.08
88342		<1%	30	$435.60
G0378	Hospital observation service, per hour	<1%	231	$421.60
85049		<1%	257	$418.47
87081		<1%	55	$385.77
86235		<1%	14	$384.15
36000		<1%	176	$381.31
84703		<1%	49	$364.33
85045		<1%	246	$361.90
83721		<1%	98	$353.78
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	165	$338.03
86709		<1%	26	$321.40
73590		<1%	16	$304.63
87631		<1%	21	$303.84
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	932	$289.73
82310		<1%	27	$286.58
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	30	$266.71
82950		<1%	45	$252.22
86762		<1%	12	$246.60
84460		<1%	78	$237.22
73560		<1%	13	$229.74
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	236	$206.73
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	548	$187.43
73140		<1%	12	$176.00
J2175	Injection, meperidine hydrochloride, per 100 mg	<1%	478	$172.32
76882		<1%	13	$172.29
84075		<1%	48	$165.36
J2060	Injection, lorazepam, 2 mg	<1%	311	$164.45
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	<1%	39	$158.14
86800		<1%	14	$136.26
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	267	$134.94
87324		<1%	13	$132.17
76937		<1%	39	$128.17
86677		<1%	20	$124.32
94150		<1%	129	$117.49
93017		<1%	30	$111.80
J0780	Injection, prochlorperazine, up to 10 mg	<1%	285	$102.33
83986		<1%	14	$90.48
84155		<1%	34	$74.63
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	30	$70.66
93296		<1%	13	$59.45
J1644	Injection, heparin sodium, per 1000 units	<1%	409	$51.59
89051		<1%	18	$47.16
J1815	Injection, insulin, per 5 units	<1%	119	$36.88
97116		<1%	21	$20.09
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	156	$16.40
82040		<1%	17	$14.16
J1170	Injection, hydromorphone, up to 4 mg	<1%	96	$6.65
94664		<1%	71	$6.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	33	$0.11
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	13	$0.06
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	<1%	31	$0.01
A9270	Non-covered item or service	0%	174	$0.00
99153	Mod sedat endo service >5yrs	0%	70	$0.00
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	0%	2,559	$0.00
94760		0%	22	$0.00
41899	Unlisted procedure, dentoalveolar structures	0%	32	$0.00
97802		0%	13	$0.00
J3490	Unclassified drugs	0%	16	$0.00
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	0%	1,339	$0.00
0202U	Oncology (prostate), multianalyte, gene expression profiling	0%	122	$0.00
99001		0%	1,078	$0.00
Q0243	Injection, casirivimab and imdevimab, 2400 mg	0%	16	$0.00
93356		0%	31	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialROSE, STEVE (CHIEF FINANCIAL OFFICER)